Market icon

Will a vaccine targeting the Omicron variant be available in the US before April 1, 2022?

Market icon

Will a vaccine targeting the Omicron variant be available in the US before April 1, 2022?

If a vaccine engineered to specifically provide protection against the Omicron variant of COVID-19, whether or not it additionally protects against other variants of SARS-CoV-2, is released for public use in the US, regardless of whether its use is restricted to particular population segments, before April 1, 2022, 12:00:00 AM ET, this market will resolve to “Yes.” Otherwise this market will resolve to “No”. The source used to resolve this market will be official information released by the FDA (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) and/or other official information from the government of the United States of America. Note, this market is only for a vaccine’s availability in the United States, and does not cover any vaccine’s availability in any other country.

If a vaccine engineered to specifically provide protection against the Omicron variant of COVID-19, whether or not it additionally protects against other variants of SARS-CoV-2, is released for public use in the US, regardless of whether its use is restricted to particular population segments, before April 1, 2022, 12:00:00 AM ET, this market will resolve to “Yes.” Otherwise this market will resolve to “No”.

The source used to resolve this market will be official information released by the FDA (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) and/or other official information from the government of the United States of America.

Note, this market is only for a vaccine’s availability in the United States, and does not cover any vaccine’s availability in any other country.
Volume
$29,057
Date de fin
Apr 1, 2022
Marché ouvert
Jan 24, 2022, 7:00 PM ET
If a vaccine engineered to specifically provide protection against the Omicron variant of COVID-19, whether or not it additionally protects against other variants of SARS-CoV-2, is released for public use in the US, regardless of whether its use is restricted to particular population segments, before April 1, 2022, 12:00:00 AM ET, this market will resolve to “Yes.” Otherwise this market will resolve to “No”. The source used to resolve this market will be official information released by the FDA (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) and/or other official information from the government of the United States of America. Note, this market is only for a vaccine’s availability in the United States, and does not cover any vaccine’s availability in any other country.

Résultat proposé: No

Aucune contestation

Résultat final: No

If a vaccine engineered to specifically provide protection against the Omicron variant of COVID-19, whether or not it additionally protects against other variants of SARS-CoV-2, is released for public use in the US, regardless of whether its use is restricted to particular population segments, before April 1, 2022, 12:00:00 AM ET, this market will resolve to “Yes.” Otherwise this market will resolve to “No”. The source used to resolve this market will be official information released by the FDA (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) and/or other official information from the government of the United States of America. Note, this market is only for a vaccine’s availability in the United States, and does not cover any vaccine’s availability in any other country.

If a vaccine engineered to specifically provide protection against the Omicron variant of COVID-19, whether or not it additionally protects against other variants of SARS-CoV-2, is released for public use in the US, regardless of whether its use is restricted to particular population segments, before April 1, 2022, 12:00:00 AM ET, this market will resolve to “Yes.” Otherwise this market will resolve to “No”.

The source used to resolve this market will be official information released by the FDA (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) and/or other official information from the government of the United States of America.

Note, this market is only for a vaccine’s availability in the United States, and does not cover any vaccine’s availability in any other country.
Volume
$29,057
Date de fin
Apr 1, 2022
Marché ouvert
Jan 24, 2022, 7:00 PM ET
If a vaccine engineered to specifically provide protection against the Omicron variant of COVID-19, whether or not it additionally protects against other variants of SARS-CoV-2, is released for public use in the US, regardless of whether its use is restricted to particular population segments, before April 1, 2022, 12:00:00 AM ET, this market will resolve to “Yes.” Otherwise this market will resolve to “No”. The source used to resolve this market will be official information released by the FDA (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) and/or other official information from the government of the United States of America. Note, this market is only for a vaccine’s availability in the United States, and does not cover any vaccine’s availability in any other country.

Résultat proposé: No

Aucune contestation

Résultat final: No

Méfiez-vous des liens externes.

Questions fréquentes

« Will a vaccine targeting the Omicron variant be available in the US before April 1, 2022? » est un marché de prédiction sur Polymarket où les traders achètent et vendent des parts « Oui » ou « Non » selon qu'ils estiment que cet événement se produira ou non. La probabilité actuelle selon la communauté est de 0% pour « Yes ». Par exemple, si « Oui » est coté à 0¢, le marché attribue collectivement une probabilité de 0% que cet événement se produise. Ces cotes changent en permanence à mesure que les traders réagissent aux nouveaux développements et informations. Les parts du résultat correct sont échangeables contre $1 chacune lors de la résolution du marché.

À ce jour, « Will a vaccine targeting the Omicron variant be available in the US before April 1, 2022? » a généré $29.1K en volume total de trading depuis le lancement du marché le Jan 25, 2022. Ce niveau d'activité reflète un fort engagement de la communauté Polymarket et garantit que les cotes actuelles sont alimentées par un large bassin de participants. Vous pouvez suivre les mouvements de prix en direct et trader sur n'importe quel résultat directement sur cette page.

Pour trader sur « Will a vaccine targeting the Omicron variant be available in the US before April 1, 2022? », choisissez simplement si vous pensez que la réponse est « Oui » ou « Non ». Chaque côté a un prix actuel qui reflète la probabilité implicite du marché. Entrez votre montant et cliquez sur « Trader ». Si vous achetez des parts « Oui » et que le résultat se résout comme « Oui », chaque part rapporte $1. S'il se résout comme « Non », vos parts « Oui » rapportent $0. Vous pouvez également vendre vos parts à tout moment avant la résolution pour sécuriser un gain ou limiter une perte.

La probabilité actuelle pour « Will a vaccine targeting the Omicron variant be available in the US before April 1, 2022? » est de 0% pour « Yes ». Cela signifie que la communauté Polymarket estime actuellement qu'il y a une probabilité de 0% que cet événement se produise. Ces cotes sont mises à jour en temps réel sur la base de transactions réelles, fournissant un signal continuellement actualisé de ce que le marché attend.

Les règles de résolution de « Will a vaccine targeting the Omicron variant be available in the US before April 1, 2022? » définissent exactement ce qui doit se produire pour que chaque résultat soit déclaré gagnant, y compris les sources de données officielles utilisées pour déterminer le résultat. Vous pouvez consulter les critères de résolution complets dans la section « Règles » sur cette page au-dessus des commentaires. Nous recommandons de lire attentivement les règles avant de trader, car elles précisent les conditions exactes, les cas particuliers et les sources.